Growth Hormone Peptide Therapy Labs: What to Order First

Before your first dose, you need a clear biological picture. Growth hormone peptide therapy labs are not optional paperwork — they are the clinical foundation that separates effective, safe treatment from guesswork.

The short answer: the minimum labs you need before starting are IGF-1, fasting glucose and insulin, a thyroid panel, liver enzymes (AST/ALT/GGT), a lipid panel, cortisol, sex hormones, and a complete metabolic panel with CBC.

Each test serves a specific purpose. Together, they tell your provider whether you're a candidate, what dose makes sense, and what your baseline looks like before the peptide changes anything. Without them, you have no reference point — and no way to prove the therapy is working.

This guide covers every test, what it reveals, and how to interpret what comes back.

Why Baseline Labs Matter Before Growth Hormone Peptide Therapy

Peptides like Sermorelin, Ipamorelin, CJC-1295, and Tesamorelin don't directly introduce growth hormone into your body. They stimulate the pituitary gland to produce and release GH on its own — a mechanism that depends heavily on the health of your broader endocrine system.1

That matters because your thyroid, cortisol axis, sex hormones, and insulin sensitivity all influence how your pituitary responds to peptide signaling. If any of these are dysregulated before you start, the therapy will underperform — or cause side effects that look like poor dosing when the real issue is an undiagnosed metabolic problem.

Baseline labs also protect you legally and clinically. If your blood glucose rises during therapy, your provider needs to know whether that elevation was pre-existing or treatment-induced. Without a pre-treatment reading, that distinction is impossible.

Meto's Advanced Metabolic Lab Panel covers 60+ biomarkers across all the systems relevant to peptide candidacy — including fasting insulin, HOMA-IR, ApoB, hs-CRP, and cortisol. Order your panel here →

The Complete Growth Hormone Peptide Therapy Labs Panel

Here are the eight categories of tests to order — in priority order.

Step 1: IGF-1 (Insulin-Like Growth Factor 1)

This is the single most important test before starting any GH peptide protocol.

IGF-1 is produced by the liver in response to GH stimulation. Because growth hormone is secreted in pulses — making a single serum GH reading clinically unreliable — IGF-1 serves as the best surrogate marker for GH axis activity.2 A low IGF-1 with matching symptoms suggests GH deficiency. An already-elevated IGF-1 may indicate you don't need stimulation — or that there's an underlying issue requiring investigation before treatment.

An IGF-1 test before peptides establishes your axis status, helps calibrate the correct starting dose, and gives your provider a benchmark to measure against at 6–12 weeks. The Endocrine Society recommends IGF-1 as the preferred initial screening tool in adults with suspected GH deficiency.3

Reference ranges:

• Age 20–30: 116–358 ng/mL
• Age 30–40: 88–246 ng/mL
• Age 40–50: 71–200 ng/mL
• Age 50+: 55–166 ng/mL (values vary by lab and assay)

Step 2: Fasting Glucose, Fasting Insulin & HOMA-IR

GH peptides increase GH output, which can reduce insulin sensitivity — particularly at higher doses and in individuals with pre-existing metabolic dysfunction.4 Knowing your starting insulin resistance score matters.

Order:

• Fasting glucose (8–10 hours fasted)
• Fasting insulin
• HOMA-IR (calculated: [fasting glucose × fasting insulin] ÷ 405)

A HOMA-IR above 2.0 warrants discussion with your provider before starting. It doesn't necessarily rule out peptide therapy, but it changes the approach — lower doses, dietary adjustments, and closer monitoring.

If you're also navigating insulin resistance or prediabetes, read: Peptides for Insulin Resistance: GLP-1, Tesamorelin & Emerging Compounds

Step 3: Thyroid Panel

The thyroid and the GH axis are tightly linked. Hypothyroidism blunts pituitary GH secretion and reduces GH receptor sensitivity — meaning if your thyroid is underactive, peptides won't work as well as they should.5 Treating thyroid dysfunction before or alongside peptide therapy significantly improves outcomes.

Order the full panel, not just TSH:

• TSH (Thyroid-Stimulating Hormone)
• Free T3
• Free T4
• Reverse T3 (optional but useful in cases of chronic stress or caloric restriction)

A normal TSH with low Free T3 — common in functional hypothyroidism — still impairs GH response. Don't rely on TSH alone.

Step 4: Liver Enzymes (AST, ALT, GGT)

IGF-1 is synthesized primarily in the liver. Liver dysfunction directly affects IGF-1 production, making your IGF-1 reading misleading if you have hepatic impairment.6 A low IGF-1 in a patient with liver disease may reflect liver dysfunction rather than GH deficiency — a clinically important distinction.

Additionally, some peptides are metabolized hepatically. Elevated enzymes aren't an absolute contraindication, but they change interpretation and may signal a need for dose adjustment.

Order:

• AST (Aspartate Aminotransferase)
• ALT (Alanine Aminotransferase)
• GGT (Gamma-Glutamyl Transferase)

Step 5: Lipid Panel (Full)

GH has significant effects on lipid metabolism. GH-deficient adults typically show elevated LDL, reduced HDL, and increased visceral adiposity.7 Peptide therapy often improves lipid profiles — but your baseline tells the story of what changed and how much.

Order:

• Total Cholesterol
• LDL
• HDL
• Triglycerides
• ApoB (a superior cardiovascular risk marker; measures the number of atherogenic particles, not just their size)

Step 6: Cortisol (Morning, Fasted)

Cortisol directly suppresses GH secretion through somatostatin, the GH-inhibiting hormone.8 Chronically elevated cortisol — from stress, poor sleep, or HPA axis dysregulation — can blunt the pituitary's response to peptide therapy even if your doses are correct.

Draw cortisol between 7–9 AM fasted for the most accurate reading. A high morning cortisol (above 20 μg/dL) warrants further investigation. A low morning cortisol may indicate adrenal insufficiency, which requires assessment before GH stimulation begins.

Step 7: Sex Hormones

GH and sex steroids are closely interactive. Estrogen reduces hepatic IGF-1 production, which explains why oral estrogen therapy can lower IGF-1 independent of GH status — a critical confound if you're on HRT.9 Testosterone supports GH axis activity in both men and women.

Order for men:

• Total Testosterone
• Free Testosterone
• LH, FSH
• Estradiol (E2)
• SHBG
• DHEA-S

Order for women:

• Estradiol (E2)
• Progesterone
• LH, FSH
• Total Testosterone
• DHEA-S

For women navigating hormonal transitions alongside metabolic optimization, this connects directly: 8 Peptides Being Studied for Women's Hormonal and Metabolic Health in 2026

Step 8: Complete Blood Count (CBC) + Complete Metabolic Panel (CMP)

These are the safety net. The CMP covers kidney function (creatinine, BUN), electrolytes, and additional liver markers. The CBC screens for anemia, infection, and conditions that affect metabolic health broadly.

Neither is specific to peptide candidacy, but both establish a clean safety baseline. If anything is flagged — elevated creatinine, low hemoglobin, abnormal white cells — it gets investigated before therapy starts, not after.

Baseline Labs for GH Peptides: At a Glance

How to Read Your IGF-1 Test Before Peptides Start

Your IGF-1 result is only meaningful in context. Three factors determine what the number means:

1. Your age — IGF-1 declines naturally with age. A result of 110 ng/mL is low for a 32-year-old but within range for a 58-year-old.
2. Your symptoms — Fatigue, reduced recovery, increased visceral fat, poor sleep quality, and declining lean mass are the clinical correlates of low GH axis activity. Low IGF-1 with matching symptoms supports the case for therapy.
3. Your liver function — A low IGF-1 caused by hepatic impairment isn't a GH deficiency. Your liver enzymes confirm or deny that interpretation.

Peptide therapy is not indicated to drive IGF-1 above the age-adjusted upper limit of normal. Supraphysiological IGF-1 — particularly sustained levels above 300–400 ng/mL — has been associated with increased cell proliferation risk.10 Therapy aims to restore, not elevate beyond, normal physiology.

Growth Hormone Peptide Therapy Labs: Monitoring After You Start

Baseline labs for GH peptides are only the beginning. Once therapy starts, your provider monitors a narrower set at regular intervals.

At 6–8 weeks:

• IGF-1 (primary response marker)
• Fasting glucose and insulin
• Thyroid panel if abnormal at baseline

At 3–6 months:

• Full lipid panel
• IGF-1
• Liver enzymes
• Sex hormones (if adjustments were made)

If IGF-1 rises appropriately — toward the mid-to-upper range for your age — and your symptoms improve, the therapy is working. If IGF-1 doesn't move, the issue is usually thyroid dysfunction, cortisol suppression, inadequate pituitary reserve, or an administration problem (timing, injection technique).

Who Should Order These Labs — and Who Should Pause

Strong candidates for GH peptide therapy evaluation:

• Adults 30+ with low-normal or low IGF-1 and symptoms of GH decline (fatigue, poor recovery, visceral fat, disrupted sleep)
• Individuals post-bariatric surgery with documented metabolic changes
• Those in concurrent testosterone replacement therapy who want to optimize body composition further
• Adults with documented GH deficiency per endocrinology evaluation

Who should pause and investigate first:

• Active malignancy or a history of GH-sensitive cancers (pituitary, breast, prostate) — GH stimulation is contraindicated3
• Uncontrolled diabetes (HbA1c above 9%) — insulin sensitivity effects compound existing dysfunction
• Severe liver disease — IGF-1 interpretation is unreliable; therapy impact is unpredictable
• Untreated hypothyroidism — pituitary response will be blunted; treat thyroid first

The peptide landscape extends well beyond GH secretagogues. If you're exploring broader peptide protocols — including GLP-1s, BPC-157, and hormonal peptides — this resource is worth reading first: Peptide Therapy for PCOS — GLP-1, BPC-157 & Hormonal Peptides

What to Do With Your Results

Once your labs are in hand, you have three possible positions:

1. Clear to proceed. IGF-1 is low-normal, metabolic markers are healthy, no red flags. Your provider designs a protocol — typically starting with Ipamorelin/CJC-1295 or Sermorelin at a conservative dose — and schedules a 6–8 week follow-up IGF-1.
2. Proceed with modifications. One or more markers are out of range but not disqualifying. Your provider addresses the underlying issue (thyroid optimization, cortisol management, dietary changes for insulin resistance) while initiating therapy at a modified dose.
3. Defer and investigate. A red flag — elevated liver enzymes, very high cortisol, borderline glucose — requires further workup before peptide therapy starts. This is not a failure. It's the lab panel doing exactly what it's designed to do.

Meto's metabolic care model is built for exactly this kind of layered evaluation. You can start your clinical assessment here and work with a provider who understands where peptides fit within a broader metabolic strategy.

Also worth reading before your first appointment: Research Peptides vs Pharmaceutical Grade: Why the Difference Could Harm You — because the source of your peptide matters as much as the protocol.

Conclusion

Growth hormone peptide therapy labs are the difference between informed treatment and a biological experiment. The panel is straightforward: IGF-1, fasting glucose and insulin, thyroid function, liver enzymes, lipids, cortisol, sex hormones, and a standard CMP/CBC. Together they establish your candidacy, calibrate your dose, and give your provider the reference points needed to track your response.

No reputable provider prescribes GH peptides without them. And no patient should accept a protocol that skips them.

Order your Meto Advanced Metabolic Lab Panel — 60+ biomarkers, 3–5 day results, interpreted by a metabolic specialist.

Frequently Asked Questions

What is the most important lab to order before starting growth hormone peptide therapy?

IGF-1 (Insulin-Like Growth Factor 1) is the most critical single test. It reflects your GH axis activity better than a serum GH test, establishes your baseline, and guides dose calibration. Without it, your provider cannot accurately assess your candidacy or measure your response to therapy.

Can I start GH peptides if my IGF-1 is in the normal range?

Yes, in some cases. Many adults fall within the "normal" range for their age group but are in the lower third of that range and have clear symptoms of GH decline — fatigue, poor recovery, increased visceral fat, disrupted sleep. The decision is based on IGF-1 in context with symptoms and a full metabolic picture, not the number in isolation.

How long does it take to see changes in labs after starting growth hormone peptide therapy?

IGF-1 typically begins to rise within 4–8 weeks of starting therapy with peptides like Ipamorelin or CJC-1295. Metabolic markers — insulin sensitivity, lipid profile, body composition changes — may take 3–6 months to shift meaningfully. Retesting at 6–8 weeks gives an early read on pituitary response.

Do I need a prescription to order these labs?

In most U.S. states, you can access many of these labs through direct-to-consumer lab services. However, interpretation — particularly for IGF-1, cortisol, and sex hormones in the context of peptide therapy — requires a clinician. Meto's lab panel and provider network are designed to cover both: the data and the clinical context to use it.

Are GH peptide therapy labs covered by insurance?

Coverage varies significantly. Standard panels including TSH, fasting glucose, CBC, and CMP are commonly covered under preventive care. IGF-1 may require a documented clinical indication. Specialty labs like HOMA-IR, ApoB, and morning cortisol are often out-of-pocket. Meto's self-pay lab panel is priced transparently with no hidden costs.

What happens if my labs show a problem — does that mean I can't do peptide therapy?

Not necessarily. A flagged result means your provider investigates further before prescribing. In many cases — low thyroid function, mild insulin resistance, suboptimal cortisol — the underlying issue can be addressed first or concurrently, and peptide therapy can proceed once the foundation is stable.